Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Holdings Decreased by Holocene Advisors LP

Holocene Advisors LP decreased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 7.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,370,831 shares of the biopharmaceutical company’s stock after selling 108,844 shares during the period. Holocene Advisors LP owned about 1.29% of Intra-Cellular Therapies worth $100,304,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. True Wealth Design LLC bought a new position in Intra-Cellular Therapies during the 3rd quarter worth approximately $32,000. Summit Securities Group LLC acquired a new position in Intra-Cellular Therapies in the second quarter worth $56,000. Capital Performance Advisors LLP bought a new stake in Intra-Cellular Therapies during the third quarter valued at $74,000. CWM LLC raised its holdings in shares of Intra-Cellular Therapies by 83.9% during the second quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 626 shares during the period. Finally, Covestor Ltd raised its holdings in shares of Intra-Cellular Therapies by 40.4% during the third quarter. Covestor Ltd now owns 1,811 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 521 shares during the period. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Intra-Cellular Therapies

In related news, President Michael Halstead sold 22,869 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The transaction was disclosed in a filing with the SEC, which is available at this link. 2.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $100.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, October 30th. Piper Sandler raised Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $68.00 to $92.00 in a report on Friday, September 6th. UBS Group lowered their price objective on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. Morgan Stanley raised their target price on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $97.23.

Intra-Cellular Therapies Trading Down 1.1 %

NASDAQ:ITCI opened at $85.65 on Monday. The business’s fifty day moving average price is $80.27 and its 200 day moving average price is $75.55. The firm has a market capitalization of $9.08 billion, a price-to-earnings ratio of -98.45 and a beta of 0.97. Intra-Cellular Therapies, Inc. has a 1-year low of $58.92 and a 1-year high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $175.40 million during the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm’s quarterly revenue was up 39.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.25) EPS. Equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.